Back to top

Blueprint Medicines Slumps: BPMC Tanks 14.8% in Session

Read MoreHide Full Article

Blueprint Medicines Corporation (BPMC - Free Report) saw a big move last session, as the company’s shares fell nearly 15% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. The stock gained 19.7% from Aug 24 to Sep 18, but since Sep 18 the stocks has lost nearly 20%.

This Medical company has seen a flat track record when it comes to current year estimate revisions, as there has been no revision on either side over the past few weeks. The consensus for loss estimate hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.

BPMC currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

A better-ranked stock in the Medical-Biomedical/Genomic sector is Neogenomics Inc. (NEO - Free Report) which holds a Zacks Rank #1 (Strong Buy).

Is BPMC going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Blueprint Medicines Corporation (BPMC) - free report >>

NeoGenomics, Inc. (NEO) - free report >>

Published in